ENDRA Life Sciences Q4 net loss narrows

ENDRA Life Sciences

31/03/2026 21:29

Overview

US thermoacoustic imaging firm's Q4 operating expenses fell, narrowing net loss yr/yr

Company initiated review of strategic alternatives to maximize shareholder value

TAEUS Liver device showed strong clinical progress in feasibility and reproducibility studies

Result Drivers

COST MANAGEMENT - Co said lower operating expenses were due to streamlining and focus on core development priorities

CLINICAL PROGRESS - Co highlighted positive feasibility and reproducibility results for TAEUS Liver device

Company press release: ID:nBw3zgrzba

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$3.20 mln
Q4 Operating Expenses
$1.60 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for ENDRA Life Sciences Inc is $30.00, about 541% above its March 30 closing price of $4.68

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)